Compare Abeona Therapeutics Inc (ABEO) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs HubSpot Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while HubSpot Inc trades at $197.32 (market cap $10.50B). The key difference: HubSpot Inc is far larger — about 28.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | HUBS | |
|---|---|---|
Market Cap | $373.32M | $10.50B |
Sector | Health | Technology |
52-Week High | $7.23 | $560.90 |
52-Week Low | $4.17 | $170.39 |
Enterprise Value | $228.22M | $9.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HUBS trades at $205.23, up 6.82% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $188 and resistance at $208. Recent earnings beats and 23% revenue growth in Q1 2026 highlight robust execution. Analyst consensus is overwhelmingly bullish with an 80.85% buy rating and a $273.53 price target, suggesting significant upside from current levels.
Outlook remains positive driven by AI integration and customer growth, but high P/E of 102.02 poses valuation risk. Competition from Salesforce and SaaS sector volatility are key concerns. Net income margin improvement to 3.04% in 2025 signals profitability traction, yet investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
